Serum bilirubin has demonstrated potent antioxidant properties in vitro and in vivo, appears to be particularly effective at suppressing oxidation of lipids, and may improve endothelial function. Various studies have shown that people with low bilirubin levels have higher rates of cardiovascular disease. In support of a causal relationship, prospective studies have shown that people with genotypes causing hyperbilirubinemia have substantially lower rates of cardiovascular disease. Serum bilirubin is often measured in patients before the prescription of a statin to assess liver function. In a large population-based cohort of patients prescribed statins in the United Kingdom (nϭ130 052), a nonlinear L-shaped relationship between pretreatment bilirubin and cardiovascular disease was detected. After traditional risk factors were accounted for, the elevated risk was restricted to those with levels Ͻ10 to 15 mol/L, and the relationship was similar in men and women. Bilirubin level measured before statin prescription provides information on cardiovascular disease risk in addition to traditional factors, which may reflect a combination of otherwise unmeasured genetic and environmental exposures. See p 2556.
Synergistic Adaptations to Exercise in the Systemic and Coronary Circulations That Underlie the Warm-Up Angina Phenomenon
Patients with angina often find their symptoms are less pronounced on second compared with first exertion. This is known as the warm-up angina phenomenon, and despite being described Ͼ200 years ago it remains poorly understood. The symptomatic benefit provided by the first exertion is still discernible with standard antianginal medication and is accompanied by less ST-segment depression and ischemia-induced dysrhythmia. In patients with angina we investigated the changes in central aortic pressure and coronary artery pressure and flow beyond the culprit stenosis during first and second supine effort in the cardiac catheterization laboratory. These recordings show a number of adaptations during second exercise that act in concert to reduce left ventricular afterload and improve coronary artery blood flow. Amongst the most striking alterations occurring during second exercise are a reduction in augmentation of the central aortic systolic pressure and an increase in the intracoronary pressure wave responsible for accelerating blood flow at the onset of diastole. This pressure wave, known as the backward expansion wave, is dependent both on myocardial vascular tone and rate of relaxation. First exercise triggers adaptive changes within the myocardial and systemic circulations that reduce cardiac work and increase myocardial blood flow during subsequent exercise. These features suggest a novel underlying mechanism that may be harnessed for therapeutic benefit. See p 2565.
Myosin Light Chain Phosphorylation Is Critical for Adaptation to Cardiac Stress
Cardiac hypertrophy is a common response to circulatory or neurohumoral stressors as a mechanism to augment contractility. When the heart is under sustained stress, the hypertrophic response can evolve into decompensated heart failure, although the mechanism(s) underlying this transition remain largely unknown. The dynamics of cardiac contraction and relaxation are fundamentally related to actin-myosin interactions: Initiated by Ca 2ϩ -induced Ca 2ϩ release, Ca 2ϩ binds to troponin C, which releases tropomyosin from preventing actin participating in cross-bridge formation. A range of factors regulate this process and contribute to the adaptation of cardiac function to physiological or pathological stressors, which could suggest a prominent therapeutic strategy for heart failure. Myosin is a hexamer composed of 2 heavy chains and 2 pairs of light chains (MLC1 and MLC2) located on the rod and neck regions of the heavy chain, respectively. Phosphorylation of MLC2v has been shown to potentiate the rate and force of cardiac contraction. In this study, we demonstrated that the kinase that phosphorylates MLC2 and cardiac myosin light-chain kinase play essential roles in cardiac adaptations to pressure overload. Development of heart failure under pressure overload is attenuated by greater expression of cardiac myosin light-chain kinase without apparent adverse effects on normal cardiac function in the absence of increased loading. Thus, an increase in the expression of cardiac myosin light-chain kinase or an enhancement of its function is a potentially important therapeutic target for the treatment of heart failure resulting from pressure overload (ie, hypertensive heart failure). See p 2575.
Endothelial Nuclear Factor-B-Dependent Regulation of Arteriogenesis and Branching
Collateral circulation plays a protective role in case of an ischemic insult precipitated by the occlusion of an arterial vessel. Despite their presumed physiological and clinical importance, little is known about the manner in which collaterals develop. A thorough understanding of this process is important to any attempts at therapeutic arteriogenesis. Collaterals are thought to arise either by expansion from the preexisting vessels or by de novo growth. In either case, the key stimulus is probably mechanical in nature, such as shear stress, and not tissue ischemia per se. One well-understood signaling mechanism that controls the size and density of a vascular network is the Delta/Notch pathway. A number of studies have demonstrated that activation of Notch-1 by its ligand ␦-like ligand 4 (Dll4) leads to a decrease in vascular branching. However, the link between Dll4/Notch signaling and shear stress has not been established. Endothelial shear stress activates the transcription factor nuclear factor-B, which controls expression of a broad array of genes involved in cell adhesion and migration. In this study, we unexpectedly show that Dll4 expression is critically dependent on nuclear factor-B, likely via nuclear factor-B-dependent stabilization of hypoxia-inducible factor-1 and -2 genes. In the absence of endothelial nuclear factor-B activation, reduced Dll4 levels lead to a much greater expansion in collateral growth than seen under normal circumstances. Paradoxically, that leads to a severe impairment in tissue blood flow. Thus, although increasing collateral density is a worthy therapeutic goal, the quality of the collateral network is just as important as its size. See p 2589.
Exosomes Mediate the Cytoprotective Action of Mesenchymal Stromal Cells on Hypoxia-Induced Pulmonary Hypertension
Pulmonary arterial hypertension remains without cure despite significant progress in our understanding of its pathophysiology. Given the complex molecular and cellular pathways underlying the development of pulmonary arterial hypertension, therapies aimed at multiple pathways and cellular targets may prove to be more efficacious. Stem cell-based therapies hold such a promise because they can simultaneously target diverse signaling pathways and have long-lasting effects. Accumulating studies support an important cytoprotective, antiinflam-
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Original Research Put Into Perspective for the Practicing Clinician Volume 126 Ⅲ Number 22 Ⅲ November 27, 2012 matory role for mesenchymal stem cells with demonstrated efficacy against pulmonary hypertension in animal models of disease. We previously reported both prevention and reversal of severe pulmonary hypertension and right heart failure in a mouse model of hypoxiainduced pulmonary hypertension and have postulated a paracrine mode of mesenchymal stem cell protective functions. In this report, we show that mesenchymal stem cells secrete microvesicles (exosomes), which are the vectors of their action, being both necessary and sufficient to confer cytoprotection on the lung vasculature. We show that, potentially through epigenetic mechanisms involving microRNA signaling, mesenchymal stromal cell exosome preparations can have long-lasting therapeutic effects on pulmonary hypertension. These findings may lead to the development of alternative strategies in the field of stem cell-based therapies, at least for certain lung diseases, in that delivery of in vitro purified exosomes could substitute for the delivery of intact cells. Exosome treatment, in addition to its enhanced practicality in terms of storage and administration, does not carry the danger of oncogenic potential of donor cells, an important consideration in all stem cellbased therapies. See p 2601.
Oxysterol-Induced Soluble Endoglin Release and Its Involvement in Hypertension
Preeclampsia is one of the most severe complications of pregnancy. Characterized by systemic hypertension, proteinuria, and edema in the third trimester of pregnancy, preeclampsia is responsible for the highest rates of morbidity and mortality for both pregnant women and neonates in the developed world. Treatment of hypertension in preeclampsia is especially needed because of the absence of effective therapies except for the delivery of the baby and placenta. Hypoxia in the placenta is considered a key event in the pathogenesis of preeclampsia, whereas soluble endoglin (sEng) is a prognostic marker and plays a pathogenic role. In this article, we report that the hypoxiadependent cholesterol derivatives oxysterols, via the liver X receptors, are able to increase sEng levels in vitro and in vivo by a mechanism involving activation of matrix metalloproteinase-14. Interestingly, mice treated with oxysterols or liver X receptor agonists underwent an increase in plasmatic sEng levels and an augmentation of arterial pressure. In addition, administration of an endoglin fragment containing the matrix metalloproteinase-14 cleavage site prevented the oxysterol-dependent increase in arterial pressure and sEng levels in mice. These data reveal for the first time the involvement of the liver X receptor pathway in sEng release and its contribution to vascular homeostasis. They also suggest that administration of endoglin peptides in preeclamptic women might serve to counteract the pathogenic effect of the elevated circulating sEng. Further studies are needed to confirm the beneficial effect of these peptides in experimental models of preeclampsia and in clinical trials. See p 2612.
